Cargando…

Endothelin antagonists: new bullets against lung injury?

Acute lung injury is a syndrome of inflammation and of increased permeability of the blood–gas barrier. Endothelins are thought to exert proinflammatory effects. Kuklin and colleagues show that the endothelin receptor antagonist tezosentan reduces pulmonary edema in endotoxemic sheep, in parallel wi...

Descripción completa

Detalles Bibliográficos
Autor principal: Leeman, Marc
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1175897/
https://www.ncbi.nlm.nih.gov/pubmed/15987411
http://dx.doi.org/10.1186/cc3525
_version_ 1782124534218883072
author Leeman, Marc
author_facet Leeman, Marc
author_sort Leeman, Marc
collection PubMed
description Acute lung injury is a syndrome of inflammation and of increased permeability of the blood–gas barrier. Endothelins are thought to exert proinflammatory effects. Kuklin and colleagues show that the endothelin receptor antagonist tezosentan reduces pulmonary edema in endotoxemic sheep, in parallel with a prevention of protein kinase C-α activation. In turn, the level of some cytokines increased after tezosentan treatment. Whether these contrasting effects of endothelin blockade on inflammatory mechanisms have clinical relevance and whether these agents might benefit patients with acute lung injury is unknown.
format Text
id pubmed-1175897
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-11758972005-07-17 Endothelin antagonists: new bullets against lung injury? Leeman, Marc Crit Care Commentary Acute lung injury is a syndrome of inflammation and of increased permeability of the blood–gas barrier. Endothelins are thought to exert proinflammatory effects. Kuklin and colleagues show that the endothelin receptor antagonist tezosentan reduces pulmonary edema in endotoxemic sheep, in parallel with a prevention of protein kinase C-α activation. In turn, the level of some cytokines increased after tezosentan treatment. Whether these contrasting effects of endothelin blockade on inflammatory mechanisms have clinical relevance and whether these agents might benefit patients with acute lung injury is unknown. BioMed Central 2005 2005-04-14 /pmc/articles/PMC1175897/ /pubmed/15987411 http://dx.doi.org/10.1186/cc3525 Text en Copyright © 2005 BioMed Central Ltd
spellingShingle Commentary
Leeman, Marc
Endothelin antagonists: new bullets against lung injury?
title Endothelin antagonists: new bullets against lung injury?
title_full Endothelin antagonists: new bullets against lung injury?
title_fullStr Endothelin antagonists: new bullets against lung injury?
title_full_unstemmed Endothelin antagonists: new bullets against lung injury?
title_short Endothelin antagonists: new bullets against lung injury?
title_sort endothelin antagonists: new bullets against lung injury?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1175897/
https://www.ncbi.nlm.nih.gov/pubmed/15987411
http://dx.doi.org/10.1186/cc3525
work_keys_str_mv AT leemanmarc endothelinantagonistsnewbulletsagainstlunginjury